Compugen: Rising Bioinformatics Star
October 2000 No. 53 The #1 investment newsletter on Israeli technology companies Compugen: Rising bioinformatics star Compugen Ltd. analysis and modeling processes. Its technologies $ Nasdaq enable scientists to accelerate their research efforts (based on daily closing prices) in discovery of drugs, therapeutics, diagnostics and 20 agricultural products. 18 The field of predicting biological processes through 16 the use of mathematics has generated intense 14 interest, particularly since the advent of the Human 12 Genome Project, which created huge amounts of raw genomic and other data. The underlying biology is 10 IPO price complex, and the data are relatively unorganized, rife with errors, overlaps, duplication and missing pieces. Trading Volume, in millions These factors have made Genome Project data 0.6 exceedingly difficult to analyze. 0.4 But the potential for using this data is immense 0.2 since many human diseases are related to inadequate or poorly performing proteins. Aug 15 Sept 1 Sept 15 Thousands of additional drug targets and possible Traded: Nasdaq Symbol: CGEN cures for diseases, rather than just treatments, may Recent Price: $14 1/16 be identified through a better understanding of how 2000 High - Low: $19 1/2 - $10 1/16 proteins are regulated, inhibited or stimulated and Initial Offering Price: $10 the genetic content of cells. Shares Offered: 5,000,000 continued on page 2 Shares Outstanding: 25,975,581 Market Capitalization: $365 million In This Issue... Formed in 1993, Compugen has made a name for Compugen: Rising bioinformatics star 1 itself as a pioneer in combining advanced The Market 4 computational techniques and molecular biology.
[Show full text]